Recap: Eli Lilly Q3 Earnings

Shares of Eli Lilly LLY fell 3% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 4.05% year over year to $1.54, which missed the estimate of $1.71.

Revenue of $5,741,000,000 up by 4.82% from the same period last year, which missed the estimate of $5,910,000,000.

Outlook

The upcoming fiscal year's EPS expected to be between $7.20 and $7.40.

The upcoming fiscal year's revenue expected to be between $23,700,000,000 and $24,200,000,000.

Conference Call Details

Date: Oct 27, 2020

Time: 09:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/nkvxndgw

Price Action

Company's 52-week high was at $170.75

Company's 52-week low was at $107.54

Price action over last quarter: down 5.92%

Company Profile

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.